Microcirculation in diabetes: Implications for chronic complications and treatment of the disease;A microcirculação no diabetes: Implicações nas complicações crônicas e tratamento da doença

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 2, 2007, Pages 204-211

  De Aguiar, Luiz Guilherme K ^a   Villela, Nivaldo Ribeiro ^a   Bouskela, Eliete ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Atherosclerosis; Diabetes mellitus; Endothelium; Vascular reactivity

Indexed keywords

EID: 34248595897     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000200009     Document Type: Review

References (60)

1. Bundgaard M. Functional implications of structural differences between consecutive segments of microvascular endothelium. Microcirc Endothelium Lymphatics 1998;4:113-42.
2. Shimokawa H. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996;28:703-11.
3. Pohl U, de Wit C. A unique role of NO in the control of blood flow. News Physiol Sci 1999;14:74-80.
4. Frame MDS, Sarelius IH. Regulation of capillary perfusion by small arterioles is partially organized. Circ Res 1993;73:155-63.
5. Kollros PR, Konkle BA. Microvascular disease in diabetes mellitus. J Cardiovasc Risk 1997;4:70-5.
6. th edition. USA: McGraw-Hill; 2005. p. 2152-80.
7. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzama K, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000;49:1239-48.
8. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
9. Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex. Thromb Res 1989;55:727-35.
10. Monnier L, Follea G, Mirouze J. Antithrombin III deficiency in diabetes mellitus: influence on vascular degenerative complications. Horm Metab Res 1978;10:470-3.
11. Collen D, Lijnen HR. Fibrin-specific fibrinolysis. Ann N Y Acad Sci 1992;667:259-71.
12. Juhan-Vague I, Morange P, Christine Alessi M. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1999;1:119-24.
13. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000;36:430-6.
14. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-12.
15. Griendling KK, Fitzgerald GA. Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-6.
16. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-23.
17. Dandona P, Aljada A. Advances in diabetes for the millennium: diabetes and the endothelium. MedGenMed 2004;6(3 suppl):6-12.
18. Szmitko PE, Wang CH, Weisel RD, de Almeida J, Anderson T, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 2003;108:1017-23.
19. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;75:767-72.
20. Aljada A, Ghanim H, Mohanty P, Syed T, Dandona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 2004;80:51-7.
21. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti- inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-65.
22. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001;86:355-62.
23. Kalinowski L, Malinski T. Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Bioch Pol 2004;51:459-69.
24. Hsueh WA, Christopher JL, Quiñones MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109-17.
25. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
26. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
27. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
28. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndrome. Circulation 2004;110:1926-32.
29. Schachinger V, Zeiher AM. Prognostic implications of endothelial dysfunction: does it mean anything? Coron Artery Dis 2001;12:435-43.
30. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003;92:3J-9J.
31. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000;101:1780-4.
32. Lundmer PL, Selwyn AP, Shook TL. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Eng J Med 1986;315:1046-51.
33. Cox DA, Vita JA, Treasure CB. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-65.
34. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
35. Corretti MC, Andreson TJ, Benjamin EJ, Celerjamer D, Charbonneau F, Creager MA, et al. Guidelines for ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the braquial artery. J Am Coll Cardiol 2002;39:257-65.
36. Schroeder S, Markus E, Runald O, Meisner C, Andreas B, Pfohl M, et al. Noninvasive determination of endothelial-mediated vasodilation as a screening test for coronary artery disease: Pilot study to assess the predictive value in comparison with angina pectoris, exercise eletrocardiography and myocardial perfusion imaging. Am Heart J 1999;138:731-9.
37. Lombard WP. The blood pressure in the arterioles, capillaries and small veins of the human skin. Am J Physiol 1912;29:335-62.
38. Intaglietta M, Silverman NR, Tompkins WR. Capillary flow velocity measurements in vivo and in situ by television methods. Microvasc Res 1975;10:165-79.
39. Davis MG, Lawler JC. The capillary circulation of the skin. Some normal and pathological findings. AMA Arch Dermatol 1958;77:690-703.
40. Tooke JE. Microvascular haemodinamics in diabetes mellitus. Clin Sci 1986;70:119-25.
41. Antonios TFT, Kaski JC, Hasan KM, Brown SJ, Singer RJ. Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. Eur Heart J 2001;22:1144-8.
42. IJzerman RG, de Jongh RT, Beijk MA, van Weissenbruch MM, Delemarre-van de Waal HA, Serne EH, et al. Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 2003;33:536-42.
43. Shamin-Uzzaman QA, Pfenninger D, Kehrer C, Chakrabarti A, Kacirotii N, Rubenfire M, et al. Altered cutaneous microvascular responses to reactive hyperaemia in coronary artery disease: a comparative study with conduit vessel responses. Clin Sci 2002;103:267-73.
44. Kuller lh, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000; 20:823-9.
45. Nielson C, Lange T, Hadjokas N. Blood glucose and coronary artery disease in non-diabetics. Diabetes Care 2006;29:998-1001.
46. Singleton JR, Smith AG, Russell J, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003;52:2867-73.
47. Jörneskorg G, Kalani M, Kuhl J. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care 2005;28:1495-7.
48. Tooke JE, Goh KL. Endotheliopathy precedes type 2 diabetes. Diabetes 1998;21:2047-9.
49. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab 2003;29:6S77-87.
50. Van Leiden HA, Dekker JM, Moll AC. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002;25:1320-5.
51. de Jongh PE, Verhave JC, Pinto-Sietsma SJ. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(suppl 4):S21-4.
52. Kenchaiah S, Evans JC, Levy D. Obesity and the risk of heart failure. N Eng J Med 2002;347:305-13.
53. Sax FL, Cannon RO III, Hanson C, Epstein SE. Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function? N Eng J Med 1987;317:1366-70.
54. Pazos-Moura CC, Moura EG, Bouskela E, Torres Filho IP, Breitenbach MMD. Nailfold capillaroscopy in non-insulin dependent diabetes mellitus: blood flow velocity during rest and post-occlusive reactive hyperemia. Clin Physiol 1990;10:451-61.
55. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of the Diabetes Intervention and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-71.
56. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonilurea or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
57. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kunamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(suppl 2):B21-9.
58. Aguiar LGK, Bahia LR, Villela NR, Laflor C, Sicuro F, Wiernsperger NF, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006;29:1083-9.
59. Aguiar LGK, Laflor C, Bahia L, Villela NR, Wiernsperger N, Bottino D, et al. Metformin improves skin capillary reactivity in normoglycaemic metabolic syndrome subjects. Diab Med 2007; no prelo.
60. Bahia L, Aguiar LGK, Villela NR, Bottino D, Godoy-Matos AF, Geloneze B, et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 2007; no prelo.